锚定健康需求拓展中国眼科赛道——访参天公司中国区总裁向宇

Core Insights - The eye health industry in China is evolving from a single treatment model to a comprehensive lifecycle health management approach, creating diverse market demands and consumption scenarios [1] - Santen Pharmaceutical is increasing its resource investment in China to explore business models that align with its product attributes, aiming to develop a "second curve" for growth in the Chinese market [1] Company Strategy - Santen's "China 2.0 Strategy" focuses on embracing consumer needs beyond serious medical treatments, recognizing the diversification of healthcare supply and demand in China [2] - The strategic upgrade is encapsulated in the 'R-E-A-C-H' model, which includes Retail, E-commerce, Ahead (Bay Area project), CSO (Contract Sales Organization), and Hospital channels to enhance market penetration and business development [2] Investment and Production Capacity - Santen is investing in deep value chain integration, with a new production base in Suzhou set to have an annual capacity exceeding 800 million eye drops, enhancing supply capabilities in the Asia-Pacific region [3] - The company is committed to long-term investment in China, with its own R&D center and a top-tier professional team, aiming to leverage China's strong production capacity and innovative environment [3] Market Potential - The eye health market in China is viewed as a blue ocean with untapped potential, and Santen calls for collaboration across the industry to build a local eye care ecosystem [4] - The value of the Chinese ophthalmology market lies not only in its size but also in the potential for ecological collaboration to unlock unexploited opportunities [4]